David Nikodem, Ph.D. | Acting Chief Executive Officer
As a senior representative of Ally Bridge Group (“ABG”), Dr. Nikodem plays an important role in ABG’s biopharmaceutical investments and serves on the boards of several of ABG’s U.S.-based biopharmaceutical companies. Dr. Nikodem has more than 13 years of experience in capital markets and financial analysis of biotechnology and healthcare companies. Prior to joining ABG in 2013, Dr. Nikodem served as Portfolio Manager at Exane Asset Management where he managed a global healthcare fund. He also managed a U.S.-focused healthcare fund as a Director at BNP Paribas in New York on the long/short proprietary trading desk. During his seven years as a Portfolio Manager in the healthcare industry, Dr. Nikodem covered a diversified range of healthcare subsectors for public equities and was involved with numerous private deals. Dr. Nikodem began his Wall Street career as a biotechnology analyst at Orbitex Asset Management in 2001, followed by analyst roles at Acacia Research Investment Corporation and Blumberg Capital Management. From 1991 to 1999, Dr. Nikodem conducted basic science research at the National Institutes of Health as well as at Georgetown University, where he earned his Ph.D. in molecular biology. From 1999 to 2001, Dr. Nikodem was a patent examiner at the United States Patent and Trademark Office in Washington, D.C. Dr. Nikodem holds undergraduate degrees in Chemistry and English Language and Literature from the University of Virginia.
Feng Cao, Ph.D. | Chief Operating Officer
Dr. Cao joins AltheaDx with over fifteen years of experience in the molecular diagnostics space. Before expanding to lead Operations, Dr. Cao was AltheaDx’s VP of Software Development and Informatics, where he was responsible for the combined use of genetics, algorithm, and analytics to improve our IDgenetix® tests. Prior to joining AltheaDx, Dr. Cao held management positions at Hologic and Third Wave Technologies where he launched the Invader Call Reporter® software for molecular diagnostic IVD tests. Dr. Cao earned his doctorate in Cell Biology from Medical College of Wisconsin, his master’s degree in Computer Science from Marquette University, and his bachelor’s degree in Biology from Peking University.
Kimberly Wilson | Quality, Regulatory, and Compliance
With over twenty years of combined experience in preclinical research, diagnostic and medical device industries, Ms. Wilson brings her expertise as head of Quality, Regulatory, and Compliance at AltheaDx. She is responsible for the development, implementation and oversight of AltheaDx’s quality, regulatory, and compliance systems and programs. Ms. Wilson joined AltheaDx in 2008 and was instrumental in establishing the quality system, licensing, and accreditation for AltheaDx’s clinical laboratory. Ms. Wilson earned a B.S in Liberal Studies from National University. She is a member of Health Care Compliance Association and has served as a Director for the Pacific Regional Chapter of the Society of Quality Assurance.